STAT+ subscribers can sign up here to get it delivered to their inbox. As we count down toward the December readout of ...
Barchart on MSN3d
A High-potential Bull Put Strategy on Cassava SciencesU.S. markets have been on a historic bull run since the end of the pandemic. However, many investors may start to be wary.
Panax ginseng shows highest effectiveness in treating Alzheimer's. Learn more about AVXL's blarcamesine and SAVA's simufilam ...
Operator: Ladies and gentlemen, welcome to Cassava Sciences Report for the Third Quarter 2024. At this time, all participants are in a listen-only mode.
More U.S. investors are launching companies stateside that license technology from China, even as Congress moves to crack down on some Chinese companies through the BIOSECURE Act. Read more.
Cassava Sciences ( (SAVA) ) has released its Q3 earnings. Here is a breakdown of the information Cassava Sciences presented to its investors.
Cassava Sciences' stock is highly shorted, with potential reward tied to the upcoming Phase 3 trial results for simufilam.
Today, Benzinga's options scanner spotted 8 options trades for Cassava Sciences. This isn't normal. The overall sentiment of ...
Cassava then released the altered data in a press release and investor deck, which led the SEC to allege that the company and ...
Today, Benzinga 's options scanner spotted 11 uncommon options trades for Cassava Sciences. This isn't normal. The overall ...
Lawyers for AstraZeneca, Bristol-Myers Squibb, and Johnson & Johnson argued at a panel hearing in Philadelphia late last week ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback